Lnc-PDZD7 contributes to stemness properties and chemosensitivity in hepatocellular carcinoma through EZH2-mediated ATOH8 transcriptional repression

Journal of Experimental & Clinical Cancer Research : CR
Yi ZhangSongqing He

Abstract

Hepatocellular carcinoma (HCC) with stemness features are pivotal for tumorigenesis, chemoresistance, and progression. Long non-coding RNAs have been implicated in the regulation of HCC stemness features; however, their mechanisms remain largely unknown. Here, we found that Lnc-PDZD7 is a potential oncogene. We systematically analyzed the clinical significance and mechanism of Lnc-PDZD7 in stemness and chemosensitivity regulation. We analyzed the Lnc-PDZD7 expression levels in liver cancer tissues and cell line by qRT-PCR and In situ hybridization. Gain- and loss-of-function experiments were conducted to investigate the biological functions of Lnc-PDZD7 in stemness and chemosensitivity regulation. Bioinformatics analysis, dual-luciferase reporter assays were performed to validate that Lnc-PDZD7 competitively regulates EZH2, Moreover, chromatin immunoprecipitation assays, bisulfite genomic sequencing and Western blot were performed to evaluate the mechanisms of EZH2 repressing ATOH8. Lnc-PDZD7 is frequently upregulated in HCC tissues. Patients with high Lnc-PDZD7 expression had poorer prognoses and a poor response to adjuvant TACE therapy. Lnc-PDZD7 could promote stemness features and suppress the sensitivity of HCC cells to ant...Continue Reading

References

Oct 11, 2002·Nature·Sooryanarayana VaramballyArul M Chinnaiyan
Sep 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Celina G KleerArul M Chinnaiyan
Dec 17, 2005·Nature·Emmanuelle ViréFrançois Fuks
Feb 4, 2009·Nature Reviews. Genetics·Tim R MercerJohn S Mattick
Mar 25, 2009·Nature Reviews. Genetics·Howard Cedar, Yehudit Bergman
Nov 26, 2009·Cancer Research·Mario-Luca SuvàIvan Stamenkovic
Dec 18, 2013·Cancer Letters·Michael L O'ConnorWei Duan
Jan 17, 2014·Nature·Yvonne TayPier Paolo Pandolfi
Jan 28, 2014·Nature·Anamaria NecsuleaHenrik Kaessmann
Feb 12, 2014·Proceedings of the National Academy of Sciences of the United States of America·Maria E GonzalezCelina G Kleer
Sep 24, 2014·Nature Reviews. Gastroenterology & Hepatology·Gregory J Gores
May 13, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Sheng-xian YuanWei-ping Zhou
Jun 24, 2015·Gastroenterology·Yangyang SongXin-Yuan Guan
Apr 16, 2016·World Journal of Clinical Oncology·Irene Marchesi, Luigi Bagella
Oct 22, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Hsin-An ChenJen-Liang Su
Sep 16, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Oriana Lo ReManlio Vinciguerra
Oct 17, 2017·Nature Medicine·Xun JinJeremy N Rich

❮ Previous
Next ❯

Citations

Jan 28, 2021·Journal of Experimental & Clinical Cancer Research : CR·Gege ShuBo Tang
Dec 17, 2020·Frontiers in Cell and Developmental Biology·Guangying CuiShen Shen
Sep 10, 2020·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Tomasz KolendaKatarzyna Lamperska
Mar 11, 2021·PloS One·Laura V BownesElizabeth A Beierle
Sep 27, 2020·Pathology, Research and Practice·Hui ZhangYanli Li
Sep 24, 2021·Journal of Experimental & Clinical Cancer Research : CR·Guizhi JiaBo Tang

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
transfect
PCR
immunoprecipitation
pull-down
electrophoresis
bioluminescence imaging
ChIP

Software Mentioned

SPSS
Living Image

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.